Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F.

J Clin Oncol. 2010 Jan 20;28(3):466-74. doi: 10.1200/JCO.2009.23.3452. Epub 2009 Dec 14.

2.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.

J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2.

3.

Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysis.

Lu AT, Salpeter SR, Reeve AE, Eschrich S, Johnston PG, Barrier AJ, Bertucci F, Buckley NS, Salpeter EE, Lin AY.

Clin Colorectal Cancer. 2009 Oct;8(4):207-14. doi: 10.3816/CCC.2009.n.035. Review.

PMID:
19822511
4.

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F.

Br J Cancer. 2009 Aug 18;101(4):715-21. doi: 10.1038/sj.bjc.6605177. Epub 2009 Jul 14.

5.

BRAF mutation in metastatic colorectal cancer.

Tol J, Nagtegaal ID, Punt CJ.

N Engl J Med. 2009 Jul 2;361(1):98-9. doi: 10.1056/NEJMc0904160. No abstract available. Erratum in: N Engl J Med. 2011 Sep 1;365(9):869.

6.

Genetic prognostic and predictive markers in colorectal cancer.

Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D.

Nat Rev Cancer. 2009 Jul;9(7):489-99. doi: 10.1038/nrc2645. Epub 2009 Jun 18. Review. Erratum in: Nat Rev Cancer. 2011 Apr;11(4):309.

PMID:
19536109
7.

Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

8.

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M.

J Clin Oncol. 2009 Apr 10;27(11):1814-21. doi: 10.1200/JCO.2008.18.2071. Epub 2009 Mar 9.

9.

Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression.

Jensen SA, Vainer B, Kruhøffer M, Sørensen JB.

BMC Cancer. 2009 Jan 20;9:25. doi: 10.1186/1471-2407-9-25.

10.

A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.

Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19432-7. doi: 10.1073/pnas.0806674105. Epub 2008 Dec 2. Erratum in: Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6878. Retraction in: Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A. Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17569.

11.

Gene expression signature for recurrence in stage III colorectal cancers.

Watanabe T, Kobunai T, Sakamoto E, Yamamoto Y, Konishi T, Horiuchi A, Shimada R, Oka T, Nagawa H.

Cancer. 2009 Jan 15;115(2):283-92. doi: 10.1002/cncr.24023.

12.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

13.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

14.

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS.

Gut. 2009 Jan;58(1):90-6. doi: 10.1136/gut.2008.155473. Epub 2008 Oct 2.

15.

Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer.

Jiang Y, Casey G, Lavery IC, Zhang Y, Talantov D, Martin-McGreevy M, Skacel M, Manilich E, Mazumder A, Atkins D, Delaney CP, Wang Y.

J Mol Diagn. 2008 Jul;10(4):346-54. doi: 10.2353/jmoldx.2008.080011. Epub 2008 Jun 13.

16.

Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.

French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN.

Clin Cancer Res. 2008 Jun 1;14(11):3408-15. doi: 10.1158/1078-0432.CCR-07-1489.

17.

Molecular signature for lymphatic metastasis in colorectal carcinomas.

Croner RS, Förtsch T, Brückl WM, Rödel F, Rödel C, Papadopoulos T, Brabletz T, Kirchner T, Sachs M, Behrens J, Klein-Hitpass L, Stürzl M, Hohenberger W, Lausen B.

Ann Surg. 2008 May;247(5):803-10. doi: 10.1097/SLA.0b013e31816bcd49.

PMID:
18438117
18.

The role of molecular markers in predicting response to therapy in patients with colorectal cancer.

Shankaran V, Wisinski KB, Mulcahy MF, Benson AB 3rd.

Mol Diagn Ther. 2008;12(2):87-98. Review.

PMID:
18422373
19.

Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis.

Walther A, Houlston R, Tomlinson I.

Gut. 2008 Jul;57(7):941-50. doi: 10.1136/gut.2007.135004. Epub 2008 Mar 25. Review.

PMID:
18364437
20.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

Items per page

Supplemental Content

Write to the Help Desk